Cargando…

Associations with baseline visual acuity in 12,414 eyes starting treatment for neovascular AMD

AIMS: To determine baseline visual acuity before the start of treatment for neovascular age-related macular degeneration (AMD), compare median and visual acuity states between treatment sites and investigate the association of socio-demographic and clinical characteristics with baseline acuity. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Relton, S. D., Chi, G. C., Lotery, A. J., West, R. M., McKibbin, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219991/ https://www.ncbi.nlm.nih.gov/pubmed/36028762 http://dx.doi.org/10.1038/s41433-022-02208-x

Ejemplares similares

Associations with visual acuity outcomes after 12 months of treatment in 9401 eyes with neovascular AMD
por: Relton, SD, et al.
Publicado: (2022)

Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set
por: Lotery, A, et al.
Publicado: (2017)

Cataract surgery in neovascular AMD: impact on visual acuity and disease activity
por: Tang, Hin Yan, et al.
Publicado: (2023)

Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study
por: Holz, F G, et al.
Publicado: (2016)

Predicting Visual Acuity in Patients Treated for AMD
por: Marginean, Beatrice-Andreea, et al.
Publicado: (2022)

Vitreoretinal interface abnormalities in middle-aged adults with visual impairment in the UK Biobank study: prevalence, impact on visual acuity and associations
por: McKibbin, Martin, et al.
Publicado: (2017)

Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment
por: Wecker, Thomas, et al.
Publicado: (2019)

Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel
por: McKibbin, M, et al.
Publicado: (2015)

A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
por: Hykin, Philip, et al.
Publicado: (2016)

Impact on Visual Acuity in Neovascular Age Related Macular Degeneration (nAMD) in Europe Due to COVID-19 Pandemic Lockdown
por: Arruabarrena, Carolina, et al.
Publicado: (2021)

Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD
por: Chakravarthy, Usha, et al.
Publicado: (2021)

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
por: Veluswamy, Balaji, et al.
Publicado: (2020)

Evaluation of visual acuity in dry AMD patients after microcurrent electrical stimulation
por: Parkinson, Kevin M., et al.
Publicado: (2023)

VISUAL ACUITY OUTCOMES OF RANIBIZUMAB TREATMENT IN PATHOLOGIC MYOPIC EYES WITH MACULAR RETINOSCHISIS AND CHOROIDAL NEOVASCULARIZATION
por: Ceklic, Lala, et al.
Publicado: (2017)

Visual Acuity and Size of Choroidal Neovascularization in Highly Myopic Eyes with a Dome-Shaped Macula
por: Wang, Lu, et al.
Publicado: (2020)

Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
por: Waizel, Maria, et al.
Publicado: (2017)

Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD
por: Tsilimbaris, Miltiadis K., et al.
Publicado: (2016)

Short-Term Morphofunctional Changes in Previously Treated Neovascular AMD Eyes Switched to Brolucizumab
por: Viggiano, Pasquale, et al.
Publicado: (2022)

The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD
por: Khan, Adnan H., et al.
Publicado: (2021)

Different Outcomes of Anti-VEGF Treatment for Neovascular AMD according to Neovascular Sutypes and Baseline Features: 2-Year Real-Life Clinical Outcomes
por: Arrigo, Alessandro, et al.
Publicado: (2021)

Mechanisms of FH Protection Against Neovascular AMD
por: Borras, Céline, et al.
Publicado: (2020)

The Impact of Diabetic Retinopathy on the Choriocapillaris in Neovascular AMD
por: Viggiano, Pasquale, et al.
Publicado: (2023)

Monitoring for neovascular age-related macular degeneration (AMD) reactivation at home: the MONARCH study
por: Ward, Elizabeth, et al.
Publicado: (2020)

Evaluation of 10 AMD Associated Polymorphisms as a Cause of Choroidal Neovascularization in Highly Myopic Eyes
por: Velazquez-Villoria, Alvaro, et al.
Publicado: (2016)

Aqueous Fluid Transcriptome Profiling Differentiates Between Non-Neovascular and Neovascular AMD
por: Kaidonis, Georgia, et al.
Publicado: (2023)

Effect of Visual Feedback on the Eye Position Stability of Patients with AMD
por: González, Esther G., et al.
Publicado: (2019)

Regulation of signaling events involved in the pathophysiology of neovascular AMD
por: Wang, Haibo, et al.
Publicado: (2016)

New Therapies of Neovascular AMD—Beyond Anti-VEGFs
por: Yerramothu, Praveen
Publicado: (2018)

Gains in the current understanding of managing neovascular AMD with brolucizumab
por: Bodaghi, Bahram, et al.
Publicado: (2023)

Appropriateness of quality standards for meaningful intercentre comparisons of aflibercept service provision for neovascular age-related macular degeneration
por: Talks, J S, et al.
Publicado: (2017)

Dihydroartemisinin Inhibits Laser-Induced Choroidal Neovascularization in a Mouse Model of Neovascular AMD
por: Li, Xun, et al.
Publicado: (2022)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
por: Faatz, Henrik, et al.
Publicado: (2022)

Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update
por: Patel, Praveen J, et al.
Publicado: (2017)

Visual Function in Eyes with Intermediate AMD with and without Retinal Pigment Abnormalities
por: Schneck, Marilyn E., et al.
Publicado: (2021)

Genetic screening for neovascular AMD: cost effective…not so quick
por: Reichel, Elias
Publicado: (2015)

Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results
por: Neves Cardoso, Pedro, et al.
Publicado: (2017)

Trends in Real-World Neovascular AMD Treatment Outcomes in the UK
por: Mehta, Hemal, et al.
Publicado: (2020)

New Therapies of Neovascular AMD beyond Anti-VEGF Injections
por: Gahn, Greggory M., et al.
Publicado: (2018)

PRN Treatment of Neovascular AMD with Cycles of Three Monthly Injections
por: Banaee, Touka, et al.
Publicado: (2021)

Lentiviral delivered aflibercept OXB-203 for treatment of neovascular AMD
por: Iqball, Sharifah, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_efqhr8ndsbc3ah1u1uc0g55hr6